未登录 分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL Linhares, Yuliya; Freytes, Cesar O.; Cherry, Mohamad; Bachier, Carlos; Maris, Michael; Hoda, Daanish; Varela, Juan C.; Bellomo, Courtney; Cross, Scott; Essell, James; Fanning, Suzanne; Terebelo, Howard; Yimer, Habte; Courtright, Jay; Sharman, Jeff P.; Kostic, Ana; Vedal, Min; Ogasawara, Ken; Avilion, Ariel; Espinola, Ricardo; Yuan, Brenda; Mattar, Bassam 分享 收藏
Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen Abramson, Jeremy S.; Solomon, Scott R.; Arnason, Jon; Johnston, Patrick B.; Glass, Bertram; Bachanova, Veronika; Ibrahimi, Sami; Mielke, Stephan; Mutsaers, Pim; Hernandez-Ilizaliturri, Francisco; Izutsu, Koji; Morschhauser, Franck; Lunning, Matthew; Crotta, Alessandro; Montheard, Sandrine; Previtali, Alessandro; Ogasawara, Ken; Kamdar, Manali 分享 收藏
An IQ Consortium Perspective on Best Practices for Bioanalytical and Immunogenicity Assessment Aspects of CAR-T and TCR-T Cellular Therapies Development Gokemeijer, Jochem; Balasubramanian, Nanda; Ogasawara, Ken; Grudzinska-Goebel, Joanna; Upreti, Vijay V.; Mody, Hardik; Kasar, Siddha; Vepachedu, Venkata R.; Xu, Weifeng; Gupta, Swati; Tarcsa, Edit; Dodge, Robert; Herr, Kate; Yang, Tong-Yuan; Tourdot, Sophie; Jawa, Vibha 分享 收藏
Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR-T and TCR-T Cell Therapies: An Industry Perspective Mody, Hardik; Ogasawara, Ken; Zhu, Xu; Miles, Dale; Shastri, Prathap Nagaraja; Gokemeijer, Jochem; Liao, Michael Z.; Kasichayanula, Sreeneeranj; Yang, Tong-Yuan; Chemuturi, Nagendra; Gupta, Swati; Jawa, Vibha; Upreti, Vijay V. 分享 收藏
分享 收藏
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial Kamdar, Manali; Solomon, Scott R.; Arnason, Jon; Johnston, Patrick B.; Glass, Bertram; Bachanova, Veronika; Ibrahimi, Sami; Mielke, Stephan; Mutsaers, Pim; Hernandez-Ilizaliturri, Francisco; Izutsu, Koji; Morschhauser, Franck; Lunning, Matthew; Maloney, David G.; Crotta, Alessandro; Montheard, Sandrine; Previtali, Alessandro; Stepan, Lara; Ogasawara, Ken; Mack, Timothy; Abramson, Jeremy S. 分享 收藏
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes Zeidan, Amer M.; Boss, Isaac; Beach, C. L.; Copeland, Wilbert B.; Thompson, Ethan; Fox, Brian A.; Hasle, Vanessa E.; Ogasawara, Ken; Cavenagh, James; Silverman, Lewis R.; Voso, Maria Teresa; Hellmann, Andrzej; Tormo, Mar; O'Connor, Tim; Previtali, Alessandro; Rose, Shelonitda; Garcia-Manero, Guillermo 分享 收藏
分享 收藏
分享 收藏
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study Lisocabtagene maraleucel用于复发或难治性大b细胞淋巴瘤患者 (TRANSCEND NHL 001): 一项多中心无缝设计研究 Abramson, Jeremy S.; Palomba, M. Lia; Gordon, Leo I.; Lunning, Matthew A.; Wang, Michael; Arnason, Jon; Mehta, Amitkumar; Purev, Enkhtsetseg; Maloney, David G.; Andreadis, Charalambos; Sehgal, Alison; Solomon, Scott R.; Ghosh, Nilanjan; Albertson, Tina M.; Garcia, Jacob; Kostic, Ana; Mallaney, Mary; Ogasawara, Ken; Newhall, Kathryn; Kim, Yeonhee; Li, Daniel; Siddiqi, Tanya 分享 收藏
分享 收藏
分享 收藏
分享 收藏
.png){kind=icon}
.png){kind=icon}
.png)
.png){kind=icon}
分享.png){kind=icon}
收藏
.png)
LANCET